Skip to main content

Advertisement

ADVERTISEMENT

Biomarker Testing News

News
09/20/2022

Yvette C Terrie

Yvette C Terrie
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
09/20/2022
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study...
09/20/2022
Journal of Clinical Pathways
News
09/20/2022

Yvette C Terrie

Yvette C Terrie
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in...
09/20/2022
Journal of Clinical Pathways

Advertisement

News
09/19/2022

Craig Ostroff

Craig Ostroff
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study...
09/19/2022
Journal of Clinical Pathways
News
07/08/2022

Ellen Kurek

Ellen Kurek
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
News
06/12/2022

Ellen Kurek

Ellen Kurek
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study...
06/12/2022
Journal of Clinical Pathways

Advertisement

News
05/16/2022

Ellen Kurek

Ellen Kurek
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a...
05/16/2022
Journal of Clinical Pathways
News
04/01/2022

Janelle Bradley

Janelle Bradley
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90%...
04/01/2022
Journal of Clinical Pathways
News
06/16/2020
Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...
Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...
Adherence to the National...
06/16/2020
Journal of Clinical Pathways

Advertisement

Advertisement